To date, the magnitude of association and the quality of evidence for cutaneous squamous cell carcinoma (cSCC) and risk factors for outcomes have not been reviewed and analyzed systematically.
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Furthermore, the absolute number of cSCC-related deaths is estimated at between 3932 and 8791 annually, the upper limit of which approaches annual melanoma-related deaths. 1 The absence of a national tumor registry for cSCC complicates the analysis of prognostic factors related to outcomes on a broad scale. Therefore, our current understanding of prognostic factors is based primarily on retrospective analyses of singleinstitution cohorts, with heterogeneously reported data. The objectives of the present study were to perform a systematic review and meta-analysis of all published reports of cSCC risk factors and outcomes and to quantify the magnitude of each risk factor and the quality of the supporting data.
Methods
The study was deemed exempt from review by the Mayo Clinic Institutional Review Board. No patient informed consent was required.
Literature Search
A comprehensive and systematic search of Ovid MEDLINE InProcess & Other Non-Indexed Citations, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus was performed from each database's earliest inception to May 14, 2015, by an experienced librarian (L.J.P.), with input from the study's principal investigator (C.L.B.) and lead author (A.K.T.). Controlled vocabulary supplemented with keywords was used to search for studies of risk factors in cSCC and association with outcomes. The search strategy is outlined in the eTable in the Supplement. Bibliographies of selected review articles were reviewed for additional relevant studies. Only studies on human data published in or translated into English were included.
Eligibility Criteria
Inclusion criteria were studies of at least 10 patients with cSCC that reported comparative data associating at least 1 defined risk factor (ie, depth of invasion, perineural invasion [PNI], diameter, tumor differentiation, immunosuppression, and location on the lip, ear, temple, or cheek) and an outcome of interest (ie, recurrence, nodal metastasis, and diseasespecific death [DSD] ). Exclusion criteria for the studies included any of the following: squamous cell carcinoma (SCC) in situ, noncutaneous SCC, anogenital SCC, cSCC data that could not be extracted from data on other malignancies (eg, basal cell carcinoma and melanoma), cSCC in patients with genetic disorders that predispose to cSCC (eg, xeroderma pigmentosa), cSCC arising in scar tissue (Marjolin ulcer), and an outcome of interest present at study initiation. No limitations were imposed on the basis of treatment modality.
Data Abstraction
Two reviewers (A.K.T. and B.F.K.) independently selected studies on the basis of inclusion and exclusion criteria. Disparities in selection were resolved through discussion and ultimately by a third reviewer (C.L.B.). Studies were initially reviewed on the basis of title and abstract, and those deemed relevant were reviewed in full text to establish the final set of studies ultimately included. In cases of study duplication, the more recent and complete studies were selected for inclusion. From these studies, data were abstracted in duplicate (by A.K.T. and B.F.K.) to verify the accuracy.
Risk of Bias Assessment
Risk of bias assessment was analyzed for each article by 2 investigators (A.K.T. and B.F.K.) using the Newcastle-Ottawa Scale.
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We considered that the most important factor in determining risk of bias was the ability of a study to adjust for confounders (ie, other risk factors) using multivariable adjustment.
Statistical Analysis
From each study, we extracted or estimated the risk ratio (RR) (presented as the hazard ratio [HR] or odds ratio [OR]) for each risk factor and outcome of interest, with the 95% CI. Various association measures were assumed to be comparable statistically. Multivariable estimates were preferentially extracted when available. Meta-analysis was performed using the random-effects model, 10 reporting the RR (95% CI). The I 2 statistic 11 was also calculated to measure inconsistency, and a value exceeding 50% implied substantial heterogeneity (ie, difference in the estimates derived from each study). Forest plots were constructed for all associations of risk factors and outcomes. Analysis was conducted using statistical software (Comprehensive Meta-Analysis, version 3.0; Biostat).
Results

Literature Search
The database search identified 1156 publications and meeting abstracts. After initial review of abstracts and titles, 1034 records were excluded ( Figure 1) . The remainig 122 studies were reviewed in full text, and 36 studies were ultimately included in our analysis.
Study Characteristics and Meta-analysis
The 36 studies described 23 421 cSCCs in 17 248 patients. Five were prospective cohort studies, and 31 were retrospective studies. No randomized trials were identified. The number of patients in the included studies ranged from 41 to 6164 (Table 1) .
Analyzed risk factors and their respective associations with outcomes of recurrence, metastasis, and DSD are shown in Figure 2 , with corresponding RRs, 95% CIs, P values, I 2 statistics, and forest plots. Risk factors associated with statistically significant increased risk of recurrence were the following: Breslow thickness exceeding 2 mm (RR, 9.64; 95% CI, 
Study Quality
Scores from the Newcastle-Ottawa Scale are listed in Table 2 , with risk assessments for each study. Six studies (16.7%) were deemed to have low risk of bias due to the presence of multivariable data, and the other 30 studies (83.3%) were of high or unclear risk owing to a lack of adjustment for confounding variables. The number of studies for each risk factor ranged from 1 to 15. Risk factor and outcome associations are shown in Figure 2 , which visually depicts them in a forest plot.
Discussion
The pooled data for most of the risk factors showed a statistically significant association with the outcomes of interest. However, some previously reported risk factors for each outcome did not have a statistically significant association. Since the 1992 publication of cSCC outcomes by Rowe et al, 43 (Table 3) . While the BWH system was developed on the basis of a single institution's experience, the AJCC and UICC systems are based on expert consensus. The present meta-analysis summarizes the entire body of data on these previously reported risk factors. To our knowledge, our data provide the most comprehensive review of previously reported risk factors for cSCC related to the outcomes of local recurrence, metastasis, and DSD.
Local Recurrence
Optimal management of cSCC is predicated on local tumor control because local recurrence is often the first indicator of aggressive biologic behavior. 3, 47 In our analysis, tumor depth (recorded as Breslow thickness in millimeters or anatomic depth) was associated with the highest RR of local recurrence. The highest-quality comparative data on Breslow thickness are by Brantsch et al, 4 representing one of the few prospective data sets in this analysis. The AJCC staging system for cSCC 44 includes both Breslow thickness exceeding 2 mm and Clark level of at least 4 as high-risk characteristics. The largest data set describing anatomic depth is a retrospective analysis by Karia et al. 6 In that study, depth was measured by anatomic depth rather than Breslow thickness, with tumor depth beyond subcutaneous fat considered a high-risk characteristic. Although it is reassuring that the significance of tumor depth is verified through distinct methods of measure, the absence of a uniform measure and reporting contributes to data heterogeneity and ambiguity for the physician. The theoretical advantage of Breslow thickness measurement is the ability to perform refined analysis of data on a continuous numerical variable. However, from a practical perspective, measurement of Breslow thickness is limited by time and the abundant frequency of transected shave biopsy specimens. Defining depth on the basis of the anatomic depth (eg, invasion beyond subcutaneous fat) simplifies the objective measure assessed in both horizontally and vertically sectioned tissue specimens. If adopted as a standard, the parameters for association with anatomic structures (eg, depth or invasion beyond subcutaneous fat) will require strict unambiguous definition.
After tumor depth, PNI was associated with the next highest RR of local recurrence. As with tumor depth, reporting of PNI was also heterogeneous. Some articles reported PNI as a binary increases with the size of the involved nerve, with an RR of regional recurrence for nerves of less than 0.1 mm in diameter of 5.6 (95% CI, 2.0-15.9; P = .001) compared with an RR of regional recurrence for nerves of at least 0.1 mm in diameter of 10.4 (95% CI, 4.4-24.7; P < .001). The AJCC staging system for cSCC 44 includes PNI as a binary variable for high risk, whereas the BWH staging system includes PNI as a risk factor when the involved nerve is at least 0.1 mm in diameter. As with tumor depth, the uniform definition and reporting of PNI is an area of critical need. In descending order of RR, tumor diameter, location on the temple, and poor differentiation were associated with local recurrence. A cutoff of 20 mm was used for tumor diameter because it is uniformly included in the AJCC staging system, the UICC staging system, and the BWH staging system. Although 4 studies 6, 17, 24, 35 in this analysis showed statistical significance, the prospective data by Brantsch et al 4 did not demonstrate an association between tumor diameter and recurrence on multivariable analysis. However, a statistically significant increase in risk was noted on univariable analysis (HR, 3.47; 95% CI, 1.89-6.39; P < .001). Tumor location on the temple, although not part of the AJCC, UICC, or BWH staging systems, 44 was associated with a higher risk of recurrence (RR, 3.2; 95% CI, 1.1-9.0; P = .03) than tumor location on either the lip or ear, although this finding was based on a single large retrospective analysis by Schmults et al. 8 Poor differentiation was also found to have a statistically significant association with recurrence (RR, 2.66; 95% CI, 1.72-4.14; P < .01) based on the pooled data from 11 studies (References 4, 6, 17, 19, 22-24, 34, 37, 39, 41). Surprisingly, location on the lip or ear and immunosuppression were not associated with a statistically significant RR of local recurrence in the present meta-analysis. The lip 43 and ear 6,43 have been reported as risk factors in some studies, but a sufficient body of data suggests otherwise. 4, 17, 34 Both the lip and the ear are included in the AJCC system but not in the UICC and BWH systems. Immunosuppression is a notable item within the AJCC system but is not included in the staging system, and it is not part of the BWH or UICC staging system. For the purpose of the present analysis, immunosuppression was included as a general category, without further stratification. Although immunosuppression was associated with recurrence in the prospective data by Brantsch et al 4 and in certain subsets of well-defined patients (eg, those with chronic lym- The correlation between cSCC risk factors and metastasis was the most well-studied and well-represented finding in our meta-analysis. The implications of metastasis are obvious because they generally are associated with poor outcomes. 8, 49, 50 Therefore, identifying risk factors associated with metastasis in cSCC is crucial for proper staging and for early identification of high-risk patients. As with local recurrence, our study showed that tumor depth was associated with the highest RR of metastasis, regardless of whether depth is measured as Breslow thickness or anatomic depth. These results are based on 7 studies, 4,6,25,34,38,40,42 one of which presents data on both Breslow thickness and anatomic depth. 38 The RR for metastasis in our analysis was greater for Breslow thickness exceeding 2 mm than for Breslow thickness exceeding 6 mm. This finding may reflect the absolute number of patients in the studies who had nodal metastases with primary tumor depths of 2 to 6 mm vs the smaller population of patients with the same outcome and tumor depth exceeding 6 mm. No patients in the prospective data by Brantsch et al 4 had nodal metastasis with Breslow thickness of less than 2 mm. The BWH group found that the anatomic depth associated with metastasis was the 4, 6, 19, 26, 30, [38] [39] [40] were based on tumor diameter and metastasis. Poorly differentiated cSCC and metastasis represented the most wellstudied association in this analysis, with a total of 18 publications that provided comparative data (References 4-7, 13, 15, 16, 19, 25-28, 30, 34, 38-40, 42).
The remaining risk factors associated with increased RR of metastasis in this analysis were PNI (RR, 2.95; 95% CI, 2.31-3.75), location on the temple (RR, 2.82; 95% CI, 1.72-4.63), location on the ear (RR, 2.33; 95% CI, 1.67-3.23), location on the lip (RR, 2.28; 95% CI, 1.54-3.37), and immunosuppression (RR, 1.59; 95% CI, 1.07-2.37). The relative absence of heterogeneity for these risk factors is reflected in the I 2 statistics of 0%, 6%, 27%, and 0% for location on the temple, ear, and lip and immunosuppression, respectively. This absence of heterogeneity further underscores associations between these risk factors and metastasis. Tumor localization on the temple is not included as a risk factor in the AJCC, UICC, and BWH staging systems. Yet, these results suggest that it might be advisable to categorize this location with the other high-risk anatomic locations, such as the ear and lip. Furthermore, a more stratified approach to the specific type of immunosuppression (eg, human immunodeficiency virus infection, solid-organ transplant, or chronic lymphocytic leukemia) would afford greater precision in our risk analysis for metastasis in these patients.
Disease-Specific Death
Of all the outcomes, DSD had the least amount of comparative data available for analysis. The risk factor with the highest RR for DSD was diameter exceeding 20 mm (RR, 19.10; 95% CI, 5.80-62.95). However, this conclusion is based solely on 1 study by Karia et al. 6 Poor differentiation, location on the ear or lip, invasion beyond subcutaneous fat, and PNI were associated with a statistically significant increase, ranging from 4-fold to 6-fold, in the RR of DSD. Although significant, tumor depth was not as highly associated with DSD as with local recurrence and metastasis, likely a reflection of a paucity of data and the heterogeneity of available studies, reflected in the I 2 statistic of 76%.
As a risk factor for DSI, PNI had an I 2 statistic of 0%, reinforcing this association. In the single study 6 with the largest data set related to DSD, risk factors in their multivariable analysis with the greatest association with DSD were diameter exceeding 20 mm (HR, 19.1; 95% CI, 5.8-63.0; P < .001), invasion beyond subcutaneous fat (HR, 11.1; 95% CI, 3.4-35.8; P < .001), location on the ear (HR, 10.1; 95% CI, 1.8-57.0; P = .008), and poor differentiation (HR, 10.0; 95% CI, 3.4-28.9; P < .001). Only 1 study 6 (among 141 patients) that reported immunosuppression as a risk factor for DSD was included in our analysis, and the authors of that report acknowledged that their study was underpowered to assess prognostic significance. Given the increasing burden of cSCC and the estimated magnitude of DSD, the results of our analysis further emphasize the need for comprehensive reporting of these results.
Limitations
This analysis was limited by several factors. First, it is possible that there were pertinent studies that were not identified because of inherent limitations in database literature searches. Second, the quality of evidence is limited by data largely derived from single-center experiences and retrospective analyses, with heterogeneous data reporting and study design. Third, some included studies had variable and at times limited follow-up data. However, no eligibility criteria were imposed on the basis of follow-up. Rather, such limitations were reflected in the Newcastle-Ottawa Scale scoring (Table 2) . Fourth, a large number of the studies provided unadjusted estimates, and many risk factors can plausibly be codependent. Fifth, we included studies in which a small proportion of patients had SCC in the setting of scarring, a genetic disorder, or the anogenital region.
Conclusions
To our knowledge, this systematic review and meta-analysis is the largest and most comprehensive study of risk factors related to outcomes for cSCC. These results verify the signifi- b The AJCC high-risk factors include Breslow thickness exceeding 2 mm, Clark level of IV or higher, perineural invasion, primary site ear, primary site non-hair-bearing lip, or poorly differentiated histology. c The BWH high-risk factors include diameter of at least 2 cm, poorly differentiated histologic findings, perineural invasion of at least 0.1 mm, and invasion beyond subcutaneous fat (excluding bone invasion, which automatically upgrades a tumor to BWH T3).
